{
  "id": "laboratory-test",
  "title": "Laboratory Test",
  "lang": "en",
  "source_lang": "en",
  "summary": "A laboratory test examines biological material to provide information about health, disease, treatment response, or public health.",
  "category": "health",
  "subcategory": "medicine",
  "type": "concept",
  "aliases": [
    "Clinical laboratory test",
    "Medical laboratory test",
    "Laboratory investigation"
  ],
  "generated_at": "2026-11-02",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/laboratory-test/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/laboratory-test/",
      "json": "https://aiwiki.page/zh/laboratory-test.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "A laboratory test is a procedure that examines a sample of biological material to obtain information about its chemical composition, cellular structure, microorganisms, genetic characteristics, or other measurable properties. In clinical medicine, laboratory tests support the detection, classification, and monitoring of disease, assessment of organ function, selection of treatment, and prevention of avoidable harm. Samples include blood, urine, stool, saliva, respiratory secretions, tissue, and fluids collected from body cavities. Although many tests are performed in specialized laboratories, others use portable instruments, bedside devices, or home-testing systems.\n\nLaboratory findings are evidence rather than self-contained diagnoses. Their meaning depends on the clinical question, the characteristics of the person tested, the timing and quality of the sample, and the performance of the analytical method. A result may be quantitative, such as a sodium concentration; qualitative, such as detection of a pathogen; or descriptive, such as a microscopic assessment of cells. The complete testing process extends from deciding what to measure through specimen collection and analysis to reporting, interpretation, and clinical action."
    },
    {
      "heading": "Clinical purposes and the scope of testing",
      "text": "Laboratory testing serves several distinct purposes, and the same measurement may have different significance in each setting. In diagnosis, testing helps distinguish among possible explanations for symptoms or signs. A complete blood count, for example, can identify reduced hemoglobin concentration in a person with suspected anemia, while additional measurements help distinguish iron deficiency, impaired blood-cell production, or increased red-cell destruction. Laboratory evidence is ordinarily interpreted alongside the medical history, physical examination, and other investigations. A result that supports one diagnosis does not necessarily exclude coexisting disease.\n\nScreening differs from diagnostic investigation because it is applied to people without recognized manifestations of the condition being sought. Examples include newborn screening for selected inherited disorders and testing donated blood for specified infections. Screening programs require more than a technically accurate assay: they also require an appropriate target population, a defined pathway for confirming positive results, and evidence that earlier detection can improve outcomes. A screening result usually identifies an increased likelihood of a condition rather than establishing it. The consequences of false-positive findings are especially important when the condition is uncommon.\n\nTests also measure disease activity, prognosis, and response to treatment. In diabetes mellitus, glycated hemoglobin provides information about glycemic exposure over approximately the preceding two to three months, although red-cell lifespan and some hemoglobin variants can affect interpretation. Measurement of viral load can track the response of certain viral infections to treatment. Drug concentrations may be measured when exposure varies substantially between individuals or when the difference between effective and toxic concentrations is narrow. Such testing connects laboratory medicine with pharmacokinetics, the study of drug absorption, distribution, metabolism, and elimination.\n\nA laboratory measurement may also function as a biomarker of a biological process without directly measuring how a person feels, functions, or survives. Changes in a biomarker do not automatically establish clinical benefit; using a measurement as a surrogate endpoint requires evidence supporting that particular use. Beyond individual care, testing supports public health surveillance, outbreak investigation, blood-product safety, and assessment of environmental or occupational exposures. Clinical, research, forensic, and public-health laboratories may use similar instruments, but they differ in their purposes, reporting obligations, consent arrangements, and requirements for sample traceability."
    },
    {
      "heading": "Historical development",
      "text": "The examination of bodily fluids long predates modern laboratories. Urine was inspected for color, clarity, sediment, and odor in several medical traditions. Such observations sometimes recognized genuine physiological changes but lacked standardized collection methods, chemical specificity, and reliable reference measurements. The development of microscopy in the seventeenth century made previously invisible structures accessible to observation. Antonie van Leeuwenhoek’s observations of microorganisms in the 1670s helped establish that biological samples contained organized microscopic forms, although their role in disease was not yet understood.\n\nDuring the nineteenth century, laboratory investigation became increasingly connected with experimental physiology and hospital medicine. Chemical methods allowed substances such as glucose, urea, and proteins to be detected or estimated in bodily fluids. Microscopy enabled systematic study of blood cells, tissue changes, and microorganisms. The development of germ theory through the work of Louis Pasteur, Robert Koch, and others gave microbiological findings a causal framework. Culture techniques and differential stains made it possible to isolate and characterize organisms rather than relying only on symptoms. Hans Christian Gram introduced the staining method bearing his name in 1884; it remains an important initial method for classifying many bacteria.\n\nTwentieth-century developments greatly expanded both the range and throughput of testing. Karl Landsteiner’s identification of the ABO blood groups around 1900 provided a basis for safer blood transfusion. The introduction of the Coulter principle in the 1950s enabled automated counting and sizing of cells by changes in electrical impedance. Continuous-flow chemical analyzers, also introduced commercially in the 1950s, reduced the manual work required for routine chemistry. Rosalyn Yalow and Solomon Berson developed radioimmunoassay in the late 1950s, making very low concentrations of substances such as insulin measurable through highly specific binding reactions. Later immunoassays replaced radioactive labels with enzymes, fluorescent compounds, or light-producing reactions.\n\nMolecular methods transformed testing from the 1980s onward. The polymerase chain reaction, developed by Kary Mullis in 1983, enabled amplification of selected DNA sequences, while reverse-transcription methods extended amplification-based testing to RNA targets. Automated sequencing and high-throughput platforms subsequently allowed laboratories to examine many genes or microbial sequences in parallel. These developments did not eliminate older techniques: microscopy, culture, chemical analysis, and molecular testing answer different questions. Modern laboratories commonly combine methods, using rapid detection to identify a likely organism, culture to recover a viable isolate, and additional analysis to characterize resistance or genetic variation."
    },
    {
      "heading": "Major laboratory disciplines",
      "text": "Clinical chemistry measures substances involved in metabolism, organ function, fluid balance, and signaling. Common groups include electrolytes, glucose, lipids, enzymes, proteins, and hormones. Measurements of creatinine are used in equations that estimate glomerular filtration rate, but creatinine is also influenced by muscle mass, diet, and some medicines. Liver-related panels combine markers with different biological meanings: aminotransferases can indicate cellular injury, alkaline phosphatase may rise with impaired bile flow or increased bone turnover, and albumin reflects several processes including synthesis, distribution, and loss. A panel therefore contains complementary measurements, not interchangeable measures of a single function.\n\nHematology examines circulating blood cells and the tissues responsible for their production. Automated counts quantify red cells, white cells, and platelets, while a blood film reveals morphology that numerical counts alone may not capture. Examination of bone marrow can investigate abnormal cell production and disorders such as leukemia. Coagulation laboratories assess selected components of blood coagulation using clotting times, factor assays, and other methods. These tests interrogate particular pathways under laboratory conditions; they do not reproduce every interaction among blood vessels, platelets, coagulation proteins, and blood flow that determines bleeding or clotting in the body.\n\nClinical microbiology identifies infectious agents and helps characterize their clinical significance. Its methods include direct microscopy, antigen detection, culture, nucleic-acid detection, and measurement of the host antibody response. Culture can demonstrate viable organisms and provide material for susceptibility testing, whereas molecular methods may identify a target rapidly without recovering a living organism. An organism detected in a specimen may represent infection, colonization, or contamination, depending on the collection site and clinical setting. Microbiology results also support assessment of antimicrobial resistance and antimicrobial stewardship, although laboratory susceptibility categories must be interpreted with the infection site, drug exposure, and organism in mind.\n\nImmunology, transfusion medicine, pathology, and genetics contribute additional forms of evidence. Immunological tests measure antibodies, immune proteins, or cellular responses, including findings associated with autoimmune disease. Transfusion testing establishes blood-group characteristics and compatibility between donor and recipient. In anatomical pathology, a biopsy or surgical specimen is examined for tissue architecture and cellular abnormalities; histopathology can distinguish processes that produce similar blood-test findings. Genetic laboratories investigate chromosome changes, sequence variants, or altered gene expression. Tests used in pharmacogenomics examine inherited variation affecting drug response, while tumor testing may characterize acquired alterations relevant to cancer classification or treatment selection."
    },
    {
      "heading": "Specimens and the preanalytical phase",
      "text": "The preanalytical phase includes everything that happens before measurement: selecting the test, identifying the person, preparing for collection, obtaining the specimen, labeling it, and transporting and processing it. These steps determine whether the material reaching the analyzer adequately represents the biological state of interest. A technically precise measurement cannot correct a sample taken from the wrong person or collected under unsuitable conditions. Positive identification and labeling at collection are therefore fundamental to patient safety. The collection site and specimen type also matter: a superficial swab, a deep tissue sample, and a blood culture provide different evidence even when obtained during the same illness.\n\nBlood may be tested as whole blood, plasma, or serum. Whole blood retains cells suspended in liquid. Plasma is obtained from anticoagulated blood after separation of the cells; serum is obtained after blood has clotted and the clot has been separated. These materials are not interchangeable for every assay. Collection tubes may contain anticoagulants, clot activators, or separation gels. Ethylenediaminetetraacetic acid, commonly abbreviated EDTA, preserves cells for many hematological measurements but binds calcium and can interfere with chemistry tests if it contaminates another specimen. Citrate tubes used for coagulation testing require an appropriate blood-to-additive ratio because excess citrate can alter measured clotting times.\n\nBiological and collection-related influences can change results before analysis begins. Food intake, physical activity, posture, time of day, pregnancy, and medication exposure affect different measurements to different degrees. Prolonged tourniquet application can concentrate some blood constituents locally. Hemolysis, the rupture of red cells, may release intracellular substances such as potassium and interfere with optical or chemical measurements. Delayed separation of blood cells can also change concentrations: continued cellular metabolism consumes glucose, for example. Specimen integrity therefore depends on assay-specific limits for storage time, temperature, exposure to light, and the number of freezing and thawing cycles.\n\nNonblood specimens have their own requirements. A timed urine collection measures excretion over a specified interval and is affected by incomplete collection; a spot urine sample answers a different question. Microbiological samples can lose diagnostic value if organisms die during transport or multiply after collection. Tissue intended for routine microscopy is commonly fixed to preserve structure, whereas material intended for culture generally requires different handling. Laboratories use acceptance and rejection criteria to manage unsuitable specimens, including inadequate volume, leakage, incorrect containers, and identification discrepancies. Where replacement is difficult, as with some cerebrospinal-fluid or surgical samples, processing decisions require explicit assessment and documentation of the limitations."
    },
    {
      "heading": "Analytical methods and measurement",
      "text": "An analytical method converts a property of the specimen into an observable signal. In many chemistry assays, a reaction produces or consumes a colored compound, and an instrument measures light absorption at selected wavelengths. Enzymatic reactions provide specificity for substances such as glucose. Electrochemical methods measure electrical properties: ion-selective electrodes, for example, estimate sodium, potassium, or other ions from differences in electrical potential across selective membranes. The relationship between signal and analyte concentration is established through calibration. Calibrators assign a measurement scale, whereas control materials are used to check whether the system continues to perform acceptably.\n\nImmunoassays use the selective binding of an antibody to its target. In a sandwich format, the target is bound by capture and detection antibodies; the signal usually increases as the amount of target increases. In competitive formats, sample material competes with a labeled reagent, often producing an inverse relationship between signal and concentration. Immunoassays can measure very small amounts of hormones, proteins, or drugs, but specificity is not absolute. Cross-reacting substances, endogenous antibodies, and some supplements can interfere. High concentrations of biotin, for example, can affect certain assays that use biotin–streptavidin binding, with the direction of error depending on assay design.\n\nSeparation techniques resolve complex mixtures before measurement. Chromatography separates substances according to their interactions with a stationary phase and a moving phase. When coupled with mass spectrometry, it can identify and quantify compounds using mass-to-charge characteristics and characteristic fragmentation patterns. Such methods are important in steroid measurement, toxicology, and newborn screening. Microscopy provides spatial and morphological information rather than merely a concentration. Flow cytometry analyzes individual cells or particles passing through an illuminated detection region, combining light-scattering properties with fluorescent labels to classify cell populations or identify abnormal patterns of protein expression.\n\nNucleic-acid methods detect or characterize genetic material. In amplification-based testing, primers define a target region and enzymes generate additional copies. Fluorescent signals may be monitored during amplification, but the relationship between a reported cycle threshold and the quantity of original material depends on the method, specimen, extraction efficiency, and calibration. A positive nucleic-acid result does not necessarily demonstrate a viable organism. Sequencing can reveal particular variants or broader patterns, but interpretation depends on coverage, analytical error, and the available biological knowledge. Across methods, laboratories distinguish the limit of detection, the smallest amount reliably distinguished from absence under specified conditions, from the limit of quantification, the smallest amount that can be measured with defined performance."
    },
    {
      "heading": "Analytical performance and diagnostic accuracy",
      "text": "A test can perform well as a measurement yet have limited value for a particular diagnosis. Analytical performance concerns how reliably the method measures its target; clinical validity concerns the relationship between its result and the condition of interest. Clinical utility concerns whether using the result improves relevant decisions or outcomes. These are related but separate questions. An assay may accurately measure a molecule that occurs in several diseases, leaving uncertainty about the cause of an elevated result. Conversely, a clinically informative biomarker may be difficult to measure consistently at the low concentrations needed for a particular application.\n\nPrecision describes the agreement among repeated measurements, whereas bias describes a systematic difference from an appropriate reference value. A highly precise method can repeatedly produce the wrong value if its calibration is biased. Performance may vary across the measuring interval, and interference can affect some specimens more than others. Metrological traceability links results through a documented calibration chain to higher-order reference materials or methods where these exist. Such traceability supports comparability but does not guarantee that all assays are interchangeable, particularly when they detect different molecular forms or when no fully suitable reference system is available.\n\nFor a binary classification, sensitivity and specificity describe performance relative to a defined reference standard. Sensitivity is the proportion of people with the target condition who test positive; specificity is the proportion without the condition who test negative. Positive predictive value asks a different question: among positive results, what proportion corresponds to the condition? If \\(p\\) denotes its prevalence in the tested population, then\n\n\\[\\mathrm{PPV} = \\frac{\\mathrm{Sensitivity}\\times p} {\\mathrm{Sensitivity}\\times p+(1-\\mathrm{Specificity})(1-p)}.\\]\n\nFor example, among 10,000 people with a condition prevalence of 1%, a test with 90% sensitivity and 95% specificity would produce approximately 90 true-positive and 495 false-positive results. Its positive predictive value would be about 15.4%, despite apparently strong sensitivity and specificity. This example assumes that the stated performance applies to that population.\n\nDiagnostic performance also depends on study design. Evaluating a test only in severely affected patients and clearly healthy controls can exaggerate its usefulness in patients with uncertain or early disease. An imperfect reference standard can misclassify the new test’s results, while interpreting the reference standard with knowledge of the test result can introduce bias. Thresholds create further trade-offs: lowering a cutoff often increases sensitivity while reducing specificity. A receiver operating characteristic curve describes this relationship across thresholds, but its summary area does not establish the best clinical decision threshold or demonstrate patient benefit. Accuracy estimates therefore require information about the population, specimen, cutoff, reference standard, and uncertainty around the estimates."
    },
    {
      "heading": "Reference intervals and clinical interpretation",
      "text": "A reference interval describes the distribution of a measurement in a defined reference population. Many intervals contain the central 95% of values, bounded by the 2.5th and 97.5th percentiles. By construction, approximately 5% of results from that population fall outside such an interval. An out-of-range result is therefore not synonymous with disease, and an in-range result does not exclude it. Reference populations and partitioning matter: age, sex-related physiology, pregnancy, and developmental stage may justify different intervals. The measurement procedure also matters, so an interval established for one method cannot automatically be transferred to another.\n\nTesting many analytes increases the chance of at least one flagged result. If 20 independent measurements each have a 95% probability of falling within their respective reference intervals in a reference individual, the probability that at least one lies outside is\n\n\\[1-0.95^{20}\\approx 0.64.\\]\n\nReal laboratory measurements are often correlated, so this calculation is illustrative rather than a universal prediction. It nevertheless shows why broad panels can generate incidental abnormalities even in the absence of a newly identifiable disorder. This is one reason the meaning of an abnormal result depends on the question that prompted testing and on the pattern across related measurements.\n\nA clinical decision limit differs from a reference limit. Decision limits are thresholds associated with a diagnostic classification, risk category, or management pathway, based on clinical evidence or professional consensus. They need not coincide with the boundaries of a healthy reference population. Some applications use a sequence of measurements rather than a single threshold. In suspected myocardial infarction, for example, troponin results are interpreted with their temporal change and evidence of myocardial ischemia; an elevated concentration alone indicates myocardial injury, not necessarily infarction. The same numerical finding can consequently have different meanings in different clinical settings.\n\nResults also vary within the same person. Within-person biological variation reflects ordinary fluctuations around an individual’s physiological state, while analytical variation adds measurement noise. A change between two results may therefore occur without a substantive change in health. Reference change values estimate how large a difference must be to exceed expected analytical and biological variation under specified assumptions. Sampling intervals, treatment, acute illness, and changes in the measurement method can complicate that assessment. For qualitative tests, timing can be equally important: a sample obtained before a detectable immune response develops may yield a negative antibody result despite infection. Interpretation is thus a process of combining measurement, biological timing, and clinical probability rather than reading a flag in isolation."
    },
    {
      "heading": "Quality management, reporting, and safety",
      "text": "Laboratory quality management covers the entire testing pathway rather than only instrument performance. Before introducing a method, a laboratory establishes or verifies relevant performance characteristics, such as precision, bias, measuring interval, detection capability, and susceptibility to interference. The scope differs according to whether the procedure is an established commercial method or a substantially modified or locally developed one. Changes in reagent lots, software, calibration, or specimen type may require additional evaluation. Documentation makes it possible to establish which method, materials, and procedures produced a particular result.\n\nInternal quality control uses materials with expected behavior to identify instability during routine operation. Control results may reveal shifts, trends, excessive random variation, or other failures requiring investigation. These materials do not necessarily reproduce every feature of patient samples, so satisfactory controls cannot exclude all specimen-specific problems. External quality assessment, also called proficiency testing in some settings, compares a laboratory’s performance with that of other participants or an assigned reference value using distributed samples. Disagreement can reveal method differences, calibration problems, or procedural errors. International standard ISO 15189 specifies requirements for quality and competence in medical laboratories; accreditation against it assesses a broader system than the performance of any single assay.\n\nThe postanalytical phase includes checking results, releasing reports, communicating urgent findings, and ensuring that information reaches the responsible clinical service. Reports commonly identify the specimen, result, unit, reference interval or decision limit, and relevant limitations. Quantities require unambiguous units because different systems can express the same analyte on markedly different numerical scales. Incompatible units, transcription errors, and unclear specimen information can cause harm even when the underlying measurement is correct. Laboratories may use automated plausibility checks, comparisons with previous results, and expert review to identify findings requiring investigation before release.\n\nCritical results are findings that may indicate an immediately serious condition and require rapid communication under an established policy. The applicable limits, recipients, and escalation procedures depend on the population and service. Communication is incomplete if a result is transmitted but never acknowledged or acted upon. Laboratory information systems can support tracking, audit trails, and electronic exchange, but also introduce risks from incorrect patient matching, faulty interface mapping, or inappropriate automated rules. Data privacy is particularly important because laboratory records may reveal infections, inherited characteristics, reproductive information, or other sensitive details. Quality systems therefore connect analytical reliability with confidentiality, traceability, and the practical reliability of clinical communication."
    },
    {
      "heading": "Testing settings, access, and emerging technologies",
      "text": "Central laboratories can concentrate expertise, automation, and complex equipment, allowing high throughput and specialized testing. Their limitations include transport time and the distance between collection and analysis. Point-of-care testing moves measurement near the patient, including emergency departments, clinics, ambulances, and homes. Examples include portable glucose meters, blood-gas analyzers, and rapid infectious-disease assays. A shorter analytical turnaround time does not necessarily mean a shorter time to an effective clinical decision: collection, staffing, result integration, and access to treatment remain important. Decentralized testing also requires operator training, quality control, maintenance, and clear responsibility for unexpected or technically invalid results.\n\nSelf-testing changes who collects the sample, performs the procedure, and interprets the output. Some products provide an immediate result, whereas direct-to-consumer services send samples to a laboratory. Performance depends on both the assay and its use outside controlled conditions. Collection errors, storage conditions, misunderstanding of instructions, and testing at an unsuitable time can affect results. Broad commercial panels can also identify findings of uncertain significance, creating further investigations without a demonstrated benefit. Overdiagnosis is distinct from a false positive: it is the correct detection of a condition that would not have caused symptoms or harm during the person’s lifetime. These consequences are evaluated at the level of the testing strategy, not merely the accuracy of the device.\n\nAccess to laboratory services is uneven within and between health systems. Equipment requires reliable power, water where applicable, maintenance, trained staff, reagents, and supply chains. A donated analyzer may remain unusable if compatible consumables or technical support are unavailable. The World Health Organization published its first Model List of Essential In Vitro Diagnostics in 2018 to support the selection and availability of priority tests. Appropriate networks combine basic testing close to patients with referral pathways for more specialized work. Transport arrangements, turnaround times, and return of results are as important to effective access as the physical presence of an instrument.\n\nNewer platforms increasingly measure many targets in one analysis. Multiplex pathogen panels can detect several organisms rapidly, but detection may include colonizing organisms or residual nucleic acid unrelated to the current illness. Broad sequencing and other large-scale molecular measurements can reveal previously inaccessible biological patterns while creating substantial interpretive demands. Artificial intelligence is being applied to cell classification, tissue-image analysis, instrument monitoring, and interpretation of complex data. Its performance depends on representative development data, independent evaluation, and monitoring after deployment. A model can learn differences between laboratories or instruments rather than disease biology, and changes in specimens, workflows, or patient populations can reduce its reliability. The evidence required for adoption therefore includes not only analytical accuracy but reproducibility, clinical validity, and the consequences of using the output in a defined care pathway."
    }
  ],
  "links": [
    "medicine",
    "diagnosis",
    "complete-blood-count",
    "anemia",
    "medical-history",
    "physical-examination",
    "diabetes-mellitus",
    "glycated-hemoglobin",
    "pharmacokinetics",
    "biomarker",
    "surrogate-endpoint",
    "public-health-surveillance",
    "germ-theory-of-disease",
    "blood-transfusion",
    "insulin",
    "polymerase-chain-reaction",
    "metabolism",
    "hormone",
    "bone-marrow",
    "leukemia",
    "antimicrobial-resistance",
    "autoimmune-disease",
    "biopsy",
    "histopathology",
    "pharmacogenomics",
    "patient-safety",
    "hemolysis",
    "antibody",
    "chromatography",
    "mass-spectrometry",
    "flow-cytometry",
    "data-privacy",
    "overdiagnosis",
    "world-health-organization",
    "artificial-intelligence"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}